News >

Vemurafenib/Cobimetinib Shows Long-Term OS Benefit in BRAF+ Melanoma

Gina Columbus @ginacolumbusonc
Published: Monday, Nov 18, 2019

Antoni Ribas, MD, a professor in the Department of Medicine at University of California in Los Angeles Jonsson Comprehensive Cancer Center

Antoni Ribas, MD

The combination of vemurafenib (Zelboraf) and cobimetinib (Cotellic) led to a 5-year overall survival (OS) rate of nearly 40% in patients with BRAF V600E–mutant metastatic melanoma who had not received prior therapy with a BRAF inhibitor, according to updated phase I findings from the BRIM7 trial (NCT01271803) published in Clinical Cancer Research.1,2
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication